Clinuvel Pharmaceuticals Ltd 6-K, filed Aug 27, 2026
Clinuvel Pharmaceuticals Ltd (CUVL)
About this 6-K
Clinuvel Pharmaceuticals Ltd filed this 6-K on August 27, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2026
Commission File Number: 001-43353
CLINUVEL PHARMACEUTICALS LIMITED
Level 22, 535 Bourke Street
Melbourne, VIC 3000
Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On August 27, 2026, Clinuvel Pharmaceuticals Limited filed various documents with the Australian Securities Exchange, a copy of each of which are attached as exhibits to this Form 6-K.
Exhibits
| Exhibit
No. |
Description | |
| 99.1 | Annual Report | |
| 99.2 | Corporate Governance Disclosure | |
| 99.3 | Appendix 4G - Key to Disclosures Corporate Governance Council Principles and Recommendations | |
| 99.4 | Presentation | |
| 99.5 | Press release | |
| 99.6 | Press release | |
| 99.7 | Press release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CLINUVEL PHARMACEUTICALS LIMITED | ||
| Date: August 27, 2026 | By: | /s/ Philippe Wolgen |
| Name: | Philippe Wolgen | |
| Title: | Managing Director and Chief Executive Officer | |
Exhibit 99.1
Exhibit 99.2
Exhibit 99.3
Exhibit 99.4
Exhibit 99.5
Exhibit 99.6
Exhibit 99.7
